Pharma& Schweiz founders Elmar Zagler (L) and Frank Rotmann

April 10, 2023 10:51 AM EDT

Facing Chapter 11, Clovis sells Rubraca rights to Swiss pharma for $70M

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Updated: Omada Health rose 21% in its public market debut

At a crossroads, biotechs are passing on reverse mergers in 2025

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...